ES533170A0 - Preparacion de igf y egf de humano por tecnologia de adn recombinante - Google Patents

Preparacion de igf y egf de humano por tecnologia de adn recombinante

Info

Publication number
ES533170A0
ES533170A0 ES533170A ES533170A ES533170A0 ES 533170 A0 ES533170 A0 ES 533170A0 ES 533170 A ES533170 A ES 533170A ES 533170 A ES533170 A ES 533170A ES 533170 A0 ES533170 A0 ES 533170A0
Authority
ES
Spain
Prior art keywords
egf
preparation
recombinant dna
dna technology
human igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES533170A
Other languages
English (en)
Other versions
ES8603955A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES533170(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES8603955A1 publication Critical patent/ES8603955A1/es
Publication of ES533170A0 publication Critical patent/ES533170A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES533170A 1983-06-06 1984-06-06 Preparacion de igf y egf de humano por tecnologia de adn recombinante Expired ES8603955A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50135383A 1983-06-06 1983-06-06
US50607883A 1983-06-20 1983-06-20

Publications (2)

Publication Number Publication Date
ES8603955A1 ES8603955A1 (es) 1986-01-16
ES533170A0 true ES533170A0 (es) 1986-01-16

Family

ID=27053789

Family Applications (1)

Application Number Title Priority Date Filing Date
ES533170A Expired ES8603955A1 (es) 1983-06-06 1984-06-06 Preparacion de igf y egf de humano por tecnologia de adn recombinante

Country Status (10)

Country Link
US (3) US6331609B1 (es)
EP (1) EP0128733B1 (es)
JP (2) JP2608870B2 (es)
KR (1) KR850000525A (es)
AU (1) AU594301B2 (es)
DE (1) DE3485693D1 (es)
DK (1) DK172480B1 (es)
ES (1) ES8603955A1 (es)
IE (1) IE58317B1 (es)
IL (1) IL71991A (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
JPS60501989A (ja) * 1983-08-10 1985-11-21 アムジエン インシュリン様成長因子の微生物発現
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
ATE85080T1 (de) * 1984-02-17 1993-02-15 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
JPS61502657A (ja) * 1984-07-13 1986-11-20 チロン　コ−ポレイシヨン プレプロインシュリン様成長因子１及び２
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
EP0193112A3 (en) * 1985-02-22 1987-02-25 The Trustees Of Columbia University In The City Of New York Cdna encoding mammalian insulin-like growth factor ii
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
US5242811A (en) * 1985-03-26 1993-09-07 Biogen, Inc. Production of human somatomedin C
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
ATE67243T1 (de) * 1985-10-21 1991-09-15 Fujisawa Pharmaceutical Co Verfahren zur herstellung von insulinaehnlichem wachstumsfaktor i (igf-i) und plasmid zu dessen herstellung.
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
IN165717B (es) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
DK175535B1 (da) * 1987-03-04 2004-11-29 Daiichi Suntory Pharma Co Ltd Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid
EP0289314B1 (en) * 1987-04-28 1994-10-12 Roche Diagnostics GmbH Use of IGF-II in the treatment of bone disorders
US5688763A (en) * 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
KR920003787B1 (ko) * 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992004363A1 (en) * 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
ATE297214T1 (de) * 1993-09-20 2005-06-15 Celtrix Pharma Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
EP0732933B1 (en) * 1993-11-15 2002-10-09 Celtrix Pharmaceuticals, Inc. Use of igf-1 and igfbp-3 in the manufacture of a medicament for treating a renal disorder
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
EP0779927A1 (en) * 1994-09-08 1997-06-25 Chiron Corporation A method of improved production of insulin-like growth factor
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US5789547A (en) * 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US7087580B2 (en) * 1998-04-23 2006-08-08 Genesense Technologies, Inc. Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
DK1165119T3 (da) 1999-04-08 2003-12-15 Genentech Inc Sammensætning baseret på modsat ladede polypeptider
US20030100505A1 (en) * 1999-11-01 2003-05-29 Chiron Corporation Compositions and methods of therapy for IGF-I-responsive conditions
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
EP1455807A2 (en) 2000-09-19 2004-09-15 Bioexpertise, Llc METHOD FOR USE OF IGF-BINDING PROTEIN FOR SELECTIVE SENSITIZATION OF TARGET CELLS i IN VIVO /i
US6887851B2 (en) 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
AU2002324672B2 (en) 2001-09-18 2007-11-08 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
ES2541673T3 (es) 2003-09-12 2015-07-23 Ipsen Biopharmaceuticals, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1)
US7595160B2 (en) * 2004-01-13 2009-09-29 U.S. Genomics, Inc. Analyte detection using barcoded polymers
EP1704256A4 (en) 2004-01-13 2008-01-16 Us Genomics Inc DETECTION AND QUANTIFICATION OF ANALYTES IN SOLUTION USING POLYMERS
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
CN101484469B (zh) 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US8580935B2 (en) 2007-02-26 2013-11-12 Alltech Associates, Inc. Ultra-fast chromatography
EP2148695B1 (en) 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP1988154B1 (en) 2007-04-30 2013-08-21 Ajinomoto Co., Inc. Method for producing human insulin-like growth factor I
EP2164509A1 (en) * 2007-06-08 2010-03-24 Massachusetts Institute of Technology Igf for the treatment of rett syndrome and synaptic disorders
US20090192554A1 (en) 2008-01-29 2009-07-30 Confluent Surgical, Inc. Bioabsorbable block copolymer
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
UA108994C2 (uk) 2009-11-17 2015-07-10 Ипсен Фарма С.А.С. Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти)
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
KR101687815B1 (ko) 2015-06-19 2016-12-20 이영근 파력 발전 장치 및 이 파력 발전 장치를 복수 개 연결한 파력 발전 시스템
MX2020002744A (es) 2017-09-11 2020-10-01 Takeda Pharmaceuticals Co Metodos y composiciones para tratar enfermedades pulmonares cronicas.
KR102015116B1 (ko) * 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
AU2021364523A1 (en) 2020-10-19 2023-04-06 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (es) 1973-07-14 1977-03-26
NL7607683A (nl) 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4652525A (en) 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4565785A (en) 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
FR2441659A1 (fr) 1978-11-14 1980-06-13 Anvar Nouveaux plasmides hybrides et microorganismes les contenant
IL60184A (en) 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
GR70279B (es) 1979-09-12 1982-09-03 Univ California
US4431740A (en) 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4350764A (en) 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE53166B1 (en) 1980-08-05 1988-08-03 Searle & Co Synthetic urogastrone gene,corresponding plasmid recombinants,transformed cells,production thereof and urogastrone expression
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
JPS57200343A (en) 1981-06-02 1982-12-08 Wakunaga Yakuhin Kk 27-desamidosecretin and its preparation
IE53517B1 (en) 1981-06-17 1988-12-07 Celltech Ltd Process for the production of a polypeptide
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
EP0108132A1 (en) 1982-05-06 1984-05-16 Applied Molecular Genetics Inc. The manufacture and expression of genes for urogastrone and polypeptide analogs thereof
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4530904A (en) 1982-09-03 1985-07-23 Eli Lilly And Company Method for conferring bacteriophage resistance to bacteria
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US5015575A (en) 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
NL8302324A (nl) 1983-06-30 1985-01-16 Rijksuniversiteit Utrecht De Escherichia coli stam, een voor deze stam karakteristiek plasmide, een werkwijze ter bereiding van dit plasmide, een precursor van een somatomedine, alsmede een groeibevorderend preparaat.
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DK108685A (da) 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
JPS61502657A (ja) 1984-07-13 1986-11-20 チロン　コ−ポレイシヨン プレプロインシュリン様成長因子１及び２
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli

Also Published As

Publication number Publication date
US6331414B1 (en) 2001-12-18
IE841400L (en) 1984-12-06
KR850000525A (ko) 1985-02-27
DE3485693D1 (de) 1992-06-11
EP0128733B1 (en) 1992-05-06
AU2913384A (en) 1984-12-13
DK276184D0 (da) 1984-06-04
EP0128733A1 (en) 1984-12-19
US6331609B1 (en) 2001-12-18
JPH0759578A (ja) 1995-03-07
IL71991A (en) 1994-05-30
DK172480B1 (da) 1998-10-05
JP2608870B2 (ja) 1997-05-14
DK276184A (da) 1985-01-21
IE58317B1 (en) 1993-09-08
USRE39355E1 (en) 2006-10-17
JPS6069029A (ja) 1985-04-19
ES8603955A1 (es) 1986-01-16
IL71991A0 (en) 1984-10-31
AU594301B2 (en) 1990-03-08

Similar Documents

Publication Publication Date Title
ES533170A0 (es) Preparacion de igf y egf de humano por tecnologia de adn recombinante
PT72322B (en) Process for preparation of recombinant dna molecules and of polipeptides similar to human interferon
NZ193487A (en) Purification of human le form interferon proteins and antibodies thereto
GB2091268B (en) Recombinant dna-molecules and methods for protein production
NL940022I1 (nl) Recombinant-dna-moleculen
DE2962359D1 (en) Method of purification of human fibroblast interferon
DK589085D0 (da) Rekombinant dna-udtrykkelsesvektor, der er funktionel og udvaelgelig iplanter
GB2042554B (en) Method for preparation of recombinant dna
NO802297L (no) Homogent fibroblast-interferon og fremstilling av dette
DK509087D0 (da) Varmebehandlet siliciumoxid-baseret tilsaetning til cement-baseret materiale
IT1160718B (it) Rivestimenti di ossido di vanadio e procedimento per applicarlo
CY1580A (en) Recombinant dna molecules and their method of production
GB8413070D0 (en) Treatment of hair loss
GB2068970B (en) Recombinant dna technique for the preparation of a protein resembling human interferon
EP0303859A3 (en) Cloning of dna encoding antibacterial polypeptide precursor and expression of the precursor
IT8521842A0 (it) Composizione refrattaria eprocedimento per ottenerla.
JPS553320A (en) Manufacture of high strength high alumina ceramics
EP0303858A3 (en) Cloning of dna encoding antibacterial polypeptide precursor and expression of the precursor
EP0256553A3 (en) Gene encoding insecticidal protein and production of said protein using said gene
ZA844207B (en) Preparation of human igf and egf via recombinant dna technology
GB2186580B (en) Purification of recombinant human interleukin-la
GB8413069D0 (en) Treatment of hair loss
JPS5795870A (en) Manufacture of alumina ceramics
GB2103220B (en) 27-desamidosecretin and production of same through recombinant dna technique
GB8427223D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20051004